|
US10711036B2
(en)
|
2015-08-28 |
2020-07-14 |
Cornell University |
MALT1 inhibitors and uses thereof
|
|
AU2016352813B2
(en)
*
|
2015-11-13 |
2019-09-19 |
Novartis Ag |
Novel pyrazolo pyrimidine derivatives
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2018165385A1
(en)
|
2017-03-08 |
2018-09-13 |
Cornell University |
Inhibitors of malt1 and uses thereof
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
AU2018395291A1
(en)
|
2017-12-28 |
2020-07-30 |
The General Hospital Corporation |
Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
|
|
EP3773576A4
(en)
|
2018-03-26 |
2021-12-29 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
FI3904350T3
(fi)
|
2018-04-12 |
2023-11-15 |
Bayer Ag |
N-(syklopropyylimetyyli)-5-(metyylisulfonyyli)-n-{1-[1-(pyrimidin-2-yyli)-1h-1,2,4-triatsol-5-yyli]etyyli}bentsamidijohdannaisia ja vastaavia pyridiinikarboksamidijohdannaisia tuholaistorjunta-aineina
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
FI3784663T3
(fi)
|
2018-04-23 |
2023-10-06 |
Celgene Corp |
Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
|
|
KR102709679B1
(ko)
|
2018-04-25 |
2024-09-26 |
바이엘 악티엔게젤샤프트 |
살충제로서의 신규 헤테로아릴-트리아졸 및 헤테로아릴-테트라졸 화합물
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN110615779B
(zh)
*
|
2018-06-20 |
2023-03-24 |
上海科技大学 |
制备来那度胺衍生物的方法
|
|
TWI848400B
(zh)
|
2018-11-28 |
2024-07-11 |
日商武田藥品工業股份有限公司 |
雜環化合物及醫藥
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
EP3941607A1
(en)
|
2019-03-21 |
2022-01-26 |
Codiak BioSciences, Inc. |
Process for preparing extracellular vesicles
|
|
US20240108747A1
(en)
|
2019-03-21 |
2024-04-04 |
Lonza Sales Ag |
Extracellular vesicle conjugates and uses thereof
|
|
AU2020301399B2
(en)
|
2019-06-24 |
2025-12-18 |
Dana-Farber Cancer Institute, Inc. |
HCK degraders and uses thereof
|
|
BR112022000942A2
(pt)
|
2019-07-23 |
2022-05-17 |
Bayer Ag |
Compostos de heteroaril-triazol como pesticidas
|
|
UY38911A
(es)
|
2019-10-09 |
2021-05-31 |
Bayer Ag |
Compuestos de heteroarilo-triazol como pesticidas, formulaciones, usos y métodos de uso de los mismos
|
|
EP4077319A1
(en)
*
|
2019-12-20 |
2022-10-26 |
Calico Life Sciences LLC |
Protein tyrosine phosphatase degraders and methods of use thereof
|
|
IL294214B2
(en)
*
|
2019-12-27 |
2026-04-01 |
Schrodinger Inc |
Cyclic compounds and methods for using them
|
|
EP4138921A1
(en)
*
|
2020-04-23 |
2023-03-01 |
University Of Iowa Research Foundation |
Gper proteolytic targeting chimeras
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
WO2021241611A1
(ja)
|
2020-05-27 |
2021-12-02 |
武田薬品工業株式会社 |
複素環化合物の製造方法
|
|
AU2021293907A1
(en)
*
|
2020-06-17 |
2023-01-19 |
Dana-Farber Cancer Institute, Inc. |
Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system
|
|
US20230235077A1
(en)
|
2020-06-24 |
2023-07-27 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
WO2022066928A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
WO2022101676A1
(en)
*
|
2020-11-12 |
2022-05-19 |
Monopteros Therapeutics,Inc. |
Materials and methods of treating cancer
|
|
AU2022207648A1
(en)
|
2021-01-13 |
2023-07-27 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
US12123053B2
(en)
|
2021-01-29 |
2024-10-22 |
Eurofins Discoverx Corporation |
Molecular glue screening assays and methods for practicing same
|
|
CN118451068A
(zh)
|
2021-12-30 |
2024-08-06 |
上海翰森生物医药科技有限公司 |
三并环类衍生物抑制剂、其制备方法和应用
|
|
EP4466268A4
(en)
*
|
2022-01-18 |
2025-12-10 |
Aurigene Oncology Ltd |
Substituted bicyclic heterocyclics used as MALT-1 inhibitors
|
|
WO2023143249A1
(zh)
*
|
2022-01-28 |
2023-08-03 |
上海齐鲁制药研究中心有限公司 |
靶向malt1的蛋白降解化合物
|
|
EP4473966A4
(en)
|
2022-02-02 |
2026-01-21 |
Ono Pharmaceutical Co |
CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT
|
|
CA3244869A1
(en)
*
|
2022-02-25 |
2023-08-31 |
Tegid Therapeutics, Inc. |
PROTACS DE MALT1
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|